How to appeal a Humana inflammatory bowel disease (crohn's + uc) denial

The framework that applies to your appeal

Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).

Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

What Humana's policy requires for inflammatory bowel disease (crohn's + uc)

Cited policy: Humana Therapeutic Drug Monitoring (Drug Levels + Anti-Drug Antibodies) for IBD Biologics

Reactive TDM at loss of response to infliximab, adalimumab, certolizumab, vedolizumab, or ustekinumab. CPT codes 80145 (IFX), 80230 (ADA), 80280 (vedolizumab), 80299 (ustekinumab). Trough drug level + anti-drug antibody assay. Once per loss-of-response episode; proactive TDM coverage variable.

How Humana denies inflammatory bowel disease (crohn's + uc) — and how to counter it

Where Humana pushes back: 1) Drug-level testing not medically necessary; 2) Empiric dose-escalation cheaper; 3) Proactive TDM not endorsed.

Counter-arguments that hold up: AGA TDM 2017 (Feuerstein Gastro 2017;153:827) — STRONG recommendation for reactive TDM at loss of response in IFX/ADA/CTZ/vedolizumab/ustekinumab. Thresholds: IFX trough >=5 µg/mL, ADA >=7.5, vedolizumab >=20 wk 6, ustekinumab >=4.5 maintenance (Adedokun Gastro 2018; Restellini AJG 2018). TAILORIX + TAXIT show reactive TDM differentiates immunogenic (anti-drug antibody → switch within class with combo immunomodulator) from mechanistic (adequate level no antibody → switch CLASS) failure — avoiding unnecessary class switch. Empiric dose escalation without TDM is wasteful and delays care.

What Humana typically denies for inflammatory bowel disease (crohn's + uc)

Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For inflammatory bowel disease (crohn's + uc), expect:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

Treatments most often denied in this category

These are the inflammatory bowel disease (crohn's + uc) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Humira (adalimumab)
• Remicade (infliximab)
• Cimzia (CD only)
• Simponi (UC only)
• Stelara (ustekinumab)
• Skyrizi (risankizumab)

How to submit the appeal to Humana

1. Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
3. File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.